MIMO healthcare Jointly Conducts Global Preclinical Trial for Mion Bio's 'Cell-Neuron' at UNR... Rokit Healthcare Joins Strategically
- Spearheading clinical trials and revaluation strategies for Mion Bio's developed pipeline, 'Cell-Neuron'
- KOSDAQ-listed Rokit Healthcare officially joins the trial to secure its 'AI Anti-aging Substance'
- Conducting global joint preclinical research with the UNR School of Medicine... Verification of biological mechanisms expected within 2026
- Embarking on follow-up research to register 'Danghasu', a natural mineral product with exclusive distribution rights, as an individually recognized health functional food
[Jan 15, 2026] Mimo Healthcare announced that it has partnered with its strategic ally, Mion Bio, to fully launch a global preclinical trial for 'Cell-Neuron', a core product targeting the improvement of mild cognitive impairment (MCI) and diabetes.
Through this preclinical trial, Mimo Healthcare is establishing the scientific foundation for Cell-Neuron, developed by Mion Bio, and taking the lead in directing the overall product revaluation strategy to expand into the global market.
■ Strategic Participation of KOSDAQ-listed Rokit Healthcare to Secure 'AI Anti-aging Substance'
Notably, KOSDAQ-listed Rokit Healthcare has officially joined this preclinical trial, drawing significant industry attention. Rokit Healthcare made the strategic decision to participate in this study to secure new 'AI anti-aging substances' for its core pipeline. With the inclusion of the publicly listed Rokit Healthcare, this project has been elevated from a straightforward product verification process to a large-scale joint industry-university-research initiative encompassing the global anti-aging and cognitive impairment improvement markets.
■ Core Pipeline 'Cell-Neuron' Targeting the 'Type 3 Diabetes' Dementia Hypothesis
'Cell-Neuron', the primary subject of this clinical trial, is an innovative product that simultaneously targets diabetes and mild cognitive impairment. It was designed based on the 'Type 3 Diabetes' hypothesis, which posits that Alzheimer's disease is closely linked to brain insulin resistance. Taking into account that the risk of dementia in diabetic patients is approximately twice as high as in the general population, the product aims at the massive global markets for both diabetes and cognitive improvement.
■ Global Joint Research with UNR School of Medicine in the U.S.
Scientific verification to secure global competitiveness is already well underway. Mimo Healthcare is currently conducting a global joint preclinical study of 'Cell-Neuron' alongside Rokit Healthcare and the University of Nevada, Reno (UNR) School of Medicine.
The research, targeted for completion this year, focuses on verifying major biological mechanisms related to the suppression of dementia and diabetes, including:
Blood glucose metabolism regulation
NGF-TRKA signaling activation
Reduction of neuroinflammation and oxidative stress
The acquired research outcomes will be utilized as a core driving force for global technology transfers and product exports in the future.
■ Follow-up Research for 'Danghasu' as an Individually Recognized Health Functional Food
In parallel, Mimo Healthcare is stepping up to strengthen the competitiveness of 'Danghasu', a natural mineral-based functional product for diabetes by Mion Bio, for which Mimo Healthcare currently holds exclusive distribution rights. Based on the results of the UNR preclinical trial, the company is concurrently proceeding with follow-up research and verification procedures to officially register 'Danghasu' as an individually recognized health functional food in South Korea.
An official from Mimo Healthcare stated, "A powerful synergy is being created by combining Mion Bio's excellent product capabilities, Rokit Healthcare's AI anti-aging R&D expertise, and our global clinical business planning skills." The official added, "By successfully completing the joint research with the UNR School of Medicine, we will secure a definitive scientific foundation in the uncharted territory of Type 3 diabetes, and lead the global healthcare market centered around Cell-Neuron and Danghasu."
MIMO healthcare Jointly Conducts Global Preclinical Trial for Mion Bio's 'Cell-Neuron' at UNR... Rokit Healthcare Joins Strategically
- Spearheading clinical trials and revaluation strategies for Mion Bio's developed pipeline, 'Cell-Neuron'
- KOSDAQ-listed Rokit Healthcare officially joins the trial to secure its 'AI Anti-aging Substance'
- Conducting global joint preclinical research with the UNR School of Medicine... Verification of biological mechanisms expected within 2026
- Embarking on follow-up research to register 'Danghasu', a natural mineral product with exclusive distribution rights, as an individually recognized health functional food
[Jan 15, 2026] Mimo Healthcare announced that it has partnered with its strategic ally, Mion Bio, to fully launch a global preclinical trial for 'Cell-Neuron', a core product targeting the improvement of mild cognitive impairment (MCI) and diabetes.
Through this preclinical trial, Mimo Healthcare is establishing the scientific foundation for Cell-Neuron, developed by Mion Bio, and taking the lead in directing the overall product revaluation strategy to expand into the global market.
■ Strategic Participation of KOSDAQ-listed Rokit Healthcare to Secure 'AI Anti-aging Substance' Notably, KOSDAQ-listed Rokit Healthcare has officially joined this preclinical trial, drawing significant industry attention. Rokit Healthcare made the strategic decision to participate in this study to secure new 'AI anti-aging substances' for its core pipeline. With the inclusion of the publicly listed Rokit Healthcare, this project has been elevated from a straightforward product verification process to a large-scale joint industry-university-research initiative encompassing the global anti-aging and cognitive impairment improvement markets.
■ Core Pipeline 'Cell-Neuron' Targeting the 'Type 3 Diabetes' Dementia Hypothesis 'Cell-Neuron', the primary subject of this clinical trial, is an innovative product that simultaneously targets diabetes and mild cognitive impairment. It was designed based on the 'Type 3 Diabetes' hypothesis, which posits that Alzheimer's disease is closely linked to brain insulin resistance. Taking into account that the risk of dementia in diabetic patients is approximately twice as high as in the general population, the product aims at the massive global markets for both diabetes and cognitive improvement.
■ Global Joint Research with UNR School of Medicine in the U.S. Scientific verification to secure global competitiveness is already well underway. Mimo Healthcare is currently conducting a global joint preclinical study of 'Cell-Neuron' alongside Rokit Healthcare and the University of Nevada, Reno (UNR) School of Medicine.
The research, targeted for completion this year, focuses on verifying major biological mechanisms related to the suppression of dementia and diabetes, including:
Blood glucose metabolism regulation
NGF-TRKA signaling activation
Reduction of neuroinflammation and oxidative stress
The acquired research outcomes will be utilized as a core driving force for global technology transfers and product exports in the future.
■ Follow-up Research for 'Danghasu' as an Individually Recognized Health Functional Food In parallel, Mimo Healthcare is stepping up to strengthen the competitiveness of 'Danghasu', a natural mineral-based functional product for diabetes by Mion Bio, for which Mimo Healthcare currently holds exclusive distribution rights. Based on the results of the UNR preclinical trial, the company is concurrently proceeding with follow-up research and verification procedures to officially register 'Danghasu' as an individually recognized health functional food in South Korea.
An official from Mimo Healthcare stated, "A powerful synergy is being created by combining Mion Bio's excellent product capabilities, Rokit Healthcare's AI anti-aging R&D expertise, and our global clinical business planning skills." The official added, "By successfully completing the joint research with the UNR School of Medicine, we will secure a definitive scientific foundation in the uncharted territory of Type 3 diabetes, and lead the global healthcare market centered around Cell-Neuron and Danghasu."